ORGANIZING COMMITTEE

Harold A. Harvey
Allan Lipton
Richard J. Santen

PROGRAM

List of Speakers ......................................................... 3267s

Introduction to the Conference, Aromatase: New Perspectives for Breast Cancer.
Richard J. Santen ......................................................... 3268s
Review of Studies on Estrogen Biosynthesis in the Human.
Pentti K. Siiteri ......................................................... 3269s

Physiology, Biochemistry, and Biological Significance

Chairpersons: Pentti K. Siiteri
Richard J. Santen

Aromatase in the Central Nervous System.
F. Naftolin and Neil J. MacLusky ........................................ 3274s
Biochemical Mechanism of Aromatization.
Jack Fishman ......................................................... 3277s
Discussion ......................................................... 3279s

Epidemiological Considerations: Aromatase, Obesity, and Breast Carcinoma

Chairpersons: Marvin A. Kirschner
Kenneth J. Ryan

Obesity, Androgens, Estrogens, and Cancer Risk.
M. A. Kirschner, G. Schneider, N.H. Ertel, and E. Worton ................. 3281s
Cyclic Ovarian Function and Breast Cancer.
Barry M. Sherman, Robert B. Wallace, and Judy A. Bean ............. 3286s
Relationship of Obesity to Blood Estrogens.
Barnett Zumoff ......................................................... 3289s
Discussion ......................................................... 3292s

In Vitro and in Vivo Assay Methodology and Biochemistry

Chairpersons: Pentti K. Siiteri
Kenneth J. Ryan

In Vitro Assays of Aromatase and Their Role in Studies of Estrogen Formation in Target Tissues.
Judith Weisz ......................................................... 3295s
Multiple Forms of Aromatase and Response of Breast Cancer Aromatase to Antiplacental Aromatase II Antibodies.
Yoshio Osawa, Buichi Tochigi, Tadayoshi Higashiyama, Carol Yarborough, Tohoru Nakamura, and Takara Yamamoto ................................. 3299s
Discussion ......................................................... 3305s

AUGUST 1982

3263s
Pharmacological Inhibitors of Aromatase: Biochemical Studies

Chairpersons: Harry Brodie
Pentti K. Siiteri

Methods and Results of Aromatization Studies in Vivo.
Christopher Longcope

Overview of Recent Development of Aromatase Inhibitors.
Angela M. H. Brodie

Basic Studies on Aminoglutethimide.
Hilton A. Salhanick

Design of Mechanism-based Inactivators of Human Placental Aromatase.
Patrick A. Marcotte and Cecil H. Robinson

A New Hypothesis Based on Suicide Substrate Inhibitor Studies for the Mechanism of Action of Aromatase.
Douglas F. Covey and William F. Hood

Discussion

Substituted C₁₉ Steroid Analogs as Inhibitors of Aromatase.
Robert W. Brueggemeier, Catherine E. Snider, and Raymond E. Counsell

Estrogen Synthesis in Human Breast Tumor and Its Inhibition by Testololactone and Bromoandrostenedione.
Thomas L. Dao

Biochemistry of Aromatase: Significance to Female Reproductive Physiology.
Kenneth J. Ryan

Pharmacological Inhibitors of Aromatase: In Vivo Studies

Chairpersons: Christopher Longcope
Richard J. Santen

In Vivo Effects of Δ¹-Testololactone on Peripheral Aromatization.
Howard L. Judd, Robert M. Barone, Larry R. Laufer, Joseph C. Gambone, Steven L. Monfort, and Bill L. Lasley

Steroid Hormone Profiles in Women Treated with Aminoglutethimide for Metastatic Carcinoma of the Breast.
E. Samojlik, R. J. Santen, M. A. Kirschner, and N. H. Ertel

In Vivo and in Vitro Pharmacological Studies of Aminoglutethimide as an Aromatase Inhibitor.

Discussion

Aromatase Inhibitors as Treatment of Animal Breast Carcinoma Models

Chairperson: Richard J. Santen

Effects of Aromatase Inhibitor 4-Hydroxyandrostenedione and Other Compounds in the 7,12-Dimethylbenz(a)anthracene-induced Breast Carcinoma Model.
Angela M. H. Brodie, Wesley M. Garrett, James R. Hendrickson, and Chon-Hwa Tsai-Morris

Discussion

Aromatase in Human Breast Carcinoma—Biochemistry: In Vitro Inhibitors

Chairpersons: Angela M. H. Brodie
William R. Miller

Significance of Aromatase Activity in Human Breast Cancer.
W. R. Miller, R. A. Hawkins, and A. P. M. Forrest

Aromatase in Human Breast Carcinoma.
E. Perei, M. E. Blackstein, and D. W. Killinger

Comparative Studies of Aromatase Inhibitors in Relation to the Significance of Estrogen Synthesis in Human Mammary Tumors.
Yusuf J. Abul-Hajj

Comparative Studies of Aromatase Inhibitors in Cultured Human Breast Cancer Cells.
J. H. MacIndoe, G. R. Woods, L. A. Etre, and D. F. Covey

A Reassessment of the Role of Breast Tumor Aromatization.
H. Leon Bradlow

Discussion
Aromatase Inhibitors as Treatment of Human Breast Carcinoma

Chairpersons: Allan Lipton
Trevor J. Powles

Δ1-Testololactone: Clinical Trials.
Albert Segaloff .......................................................... 3387s

Kenneth E. Gale .......................................................... 3389s

Adequacy of Estrogen Suppression with Aminoglutethimide and Hydrocortisone as Treatment of Human Breast Cancer: Correlation of Hormonal Data with Clinical Responses.
Richard J. Santen, Thomas J. Worgul, Eugeniusz Samojlik, Alice E. Boucher, Allan Lipton, and Harold Harvey 3397s

Aminoglutethimide in the Treatment of Metastatic Breast Cancer.
Michael B. Troner .......................................................... 3402s

Aminoglutethimide in the Treatment of Advanced Postmenopausal Breast Cancer.
Adrian L. Harris, Trevor J. Powles, and Ian E. Smith 3405s

Tamoxifen and Aminoglutethimide in Advanced Breast Cancer.
Joseph Corkery, Robert C. F. Leonard, I. Craig Henderson, Rebecca S. Gelman, Joseph Hourihan, Diane M. Ascoli, and Hilton A. Salhanick 3409s

Adjuvant Aminoglutethimide Therapy for Postmenopausal Patients with Primary Breast Cancer: Progress Report.
R. Charles Coombes, Clair Chihi, Mitch Dowsett, Jean-Claude Gazet, Hubert T. Ford, Radka Bettelheim, Caroline Gordon, Ian E. Smith, David Zava, Trevor J. Powles, and Investigators of the Collaborative Breast Cancer Project 3415s

Discussion ................................................................. 3418s

Antiestrogens as Alternative Means of Inhibiting Estrogen Action

Chairpersons: Allan Lipton
William L. McGuire

New Strategies for Investigating Antiestrogen Action in Breast Cancer.
William Leo McGuire .................................................... 3420s

Discussion ................................................................. 3422s

Antiestrogen Treatment of Breast Cancer: An Overview.
Olof H. Pearson, Andrea Manni, and Baha’uddin M. Arafah 3424s

Discussion ................................................................. 3428s

Randomized Trials of Aromatase Inhibitors versus Antiestrogens

Chairpersons: William L. McGuire
Harold A. Harvey

Tamoxifen versus Aminoglutethimide versus Combined Tamoxifen and Aminoglutethimide in the Treatment of Advanced Breast Carcinoma.
Ian E. Smith, Adrian L. Harris, Michael Morgan, Jean-Claude Gazet, and J. Alan McKinna 3430s

Discussion ................................................................. 3433s

Randomized Trial of Aminoglutethimide versus Tamoxifen in Metastatic Breast Cancer.
Allan Lipton, Harold A. Harvey, Richard J. Santen, Alice Boucher, Deborah White, Albert Bernath, Richard Dixon, George Richards, and Ahmed Shafik 3434s

Robin M. L. Murray and Paula Pitt 3437s

Discussion ................................................................. 3439s

Phase II Study of Aminoglutethimide and Medroxyprogesterone Acetate in the Treatment of Patients with Advanced Breast Cancer.
Gerd A. Nagel, Hans-Erik Wander, and Hans-Christian Blossey 3442s

Discussion ................................................................. 3444s

AUGUST 1982 3265s
Aminoglutethimide in Tamoxifen-resistant Patients

Chairpersons: Harold A. Harvey
William L. McGuire

Use of Aminoglutethimide as Second-Line Endocrine Therapy in Metastatic Breast Cancer.
Stanley B. Kaye, Robert L. Woods, Richard M. Fox, Alan S. Coates, and Martin H. N. Tattersall

3445s

Aminoglutethimide after Tamoxifen Therapy in Advanced Breast Cancer: M. D. Anderson Hospital Experience.
Aman U. Buzdar, Kimberly C. Powell, and George R. Blumenschein

3448s

Aromatase Inhibition versus Surgical Ablation

Chairpersons: Harold A. Harvey
William L. McGuire

Cross-Over Comparison of Tamoxifen and Aminoglutethimide in Advanced Breast Cancer.
Harold A. Harvey, Allan Lipton, Deborah S. White, Richard J. Santen, Alice E. Boucher, Ahmed S. Shafik, Richard J. Dixon, and Members of The Central Pennsylvania Oncology Group

3451s

Comparison of Surgical Adrenalectomy to Medical Adrenalectomy in Patients with Metastatic Carcinoma of the Breast.
Samuel A. Wells, Jr., Thomas J. Worgul, Eugeniusz Samojlik, Alice E. Boucher, Allan Lipton, Harold Harvey, Deborah White, Emma Smart, Charles Cox, and Richard J. Santen

3454s

Combinations of Agents to Inhibit Estrogenic Actions as Treatment of Breast Carcinoma

Chairpersons: William L. McGuire
Harold A. Harvey

Clinical Trial of Multiple Endocrine Therapy for Metastatic and Locally Advanced Breast Cancer with Tamoxifen-Aminoglutethimide-Danazol Compared to Tamoxifen Used Alone.
Trevor J. Powles, C. Gordon, and R. C. Coombes

3458s

Progress Report on Two Clinical Trials in Women with Advanced Breast Cancer. Trial I: Tamoxifen versus Tamoxifen plus Aminoglutethimide; Trial II: Aminoglutethimide in Patients with Prior Tamoxifen Exposure.
James N. Ingle, Stephanie J. Green, David L. Ahmann, John H. Edmonson, William C. Nichols, Stephen Frytak, and Joseph Rubin

3461s

Discussion

3464s

Closing Remarks to the Conference, Aromatase: New Perspectives for Breast Cancer.
Allan Lipton, Harold A. Harvey, and Richard J. Santen

3468s